Form EFFECT Karyopharm Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
RBC Capital Reiterates Outperform Rating on Karyopharm Therapeutics (KPTI)
June 10, 2024 5:39 AM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $3.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI)
The analyst comments "Reflecting on ASCO and digesting the latest selinexor updates, we believe the longer follow-up data in TP53wt EC, KOL perspectives... More
